Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

NCT06087640 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT06087640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06087640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Lead sponsor
Seqirus
Phase
Phase 3
Overall status
Completed
Start date
October 23, 2023
Completion date
June 15, 2026
Enrollment
38,769 (actual)
Sites
255

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human